- Home
- EVGN vs CANF Comparison
EVGN vs CANF Comparison
Compare EVGN & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EVGN | CANF |
|---|---|---|
| Founded | 1999 | 1994 |
| Country | Israel | Israel |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1M | 6.0M |
| IPO Year | 2013 | 2011 |
Fundamental Metrics
Financial Performance| Metric | EVGN | CANF |
|---|---|---|
| Price | $0.52 | $3.08 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $3.50 | ★ $50.00 |
| AVG Volume (30 Days) | ★ 384.8K | 19.5K |
| Earning Date | 05-20-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $2,715,455.50 |
| Revenue Next Year | $73.33 | $101.06 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.51 | $0.17 |
| 52 Week High | $1.50 | $10.40 |
Technical Indicators
Market Signals| Indicator | EVGN | CANF |
|---|---|---|
| Relative Strength Index (RSI) | 24.70 | 42.88 |
| Support Level | $0.52 | $2.87 |
| Resistance Level | $0.86 | $3.24 |
| Average True Range (ATR) | 0.06 | 0.15 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 7.75 | 30.77 |
Price Performance
Historical ComparisonAbout EVGN Evogene Ltd
Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules, and genetic elements as the core components for such products. It holds several subsidiaries utilizing the CPB platform for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits, and ag-solutions for castor oil production. It generates maximum revenue from the industrial segment, followed by Agriculture.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.